The latest casualty of impending drug-patent expirations is a GlaxoSmithKline plant in Kent, England. The drugmaker says it will shutter the manufacturing facility by 2013, eliminating more than 600 jobs in the process.
The layoff pain in Pharma isn't limited to the big guns. Amylin Pharmaceuticals yesterday cut 340 staffers--some 25 percent of its workforce--to save $100 million a year. The San Diego drugmaker will be left with 1,800 workers.
Disappointing sales of Amylin's diabetes med, Byetta, prompted the staffing cuts, which will include positions in administration, operations and R&D, CEO Daniel Bradbury told the San Diego Union-Tribune.